Gefitinib [cytosol]

Stable Identifier
R-ALL-1169429
Type
ChemicalDrug
Compartment
cytosol
Synonyms
Iressa, ZD1839, Reversible tyrosine kinase inhibitor gefitinib EGFR specific
Locations in the PathwayBrowser
Expand all
General
Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by AstraZeneca Pharmaceuticals. Gefitinib selectively inhibits EGFR-stimulated tumor cell growth and blocks EGFR autophosphorylation in tumor cells by competitive inhibition of ATP binding to kinase domain of EGFR (Wakeling et al. 2002, Yun et al. 2007).
Literature References
PubMed ID Title Journal Year
12384534 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy

Wakeling, AE, Guy, SP, Woodburn, JR, Ashton, SE, Curry, BJ, Barker, AJ, Gibson, KH

Cancer Res 2002
17349580 Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity

Yun, CH, Boggon, TJ, Li, Y, Woo, MS, Greulich, H, Meyerson, M, Eck, MJ

Cancer Cell 2007
External Reference Information
External Reference
gefitinib [Guide to Pharmacology:4941]
Participates
as a member of
as a component of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
ChEBI
Pharos - Ligands
PharmacoDB
Cite Us!